Asker Healthcare Group (ASKER) Q4 2024 earnings summary

Executive summary

• Net sales increased 12% to SEK 15,025m, with 17% growth on a comparable basis, driven by both organic growth and acquisitions across all business areas.

• Adjusted EBITA rose 25% to SEK 1,362m, with margin improving to 9.1% from 8.5% the previous year.

• Twelve acquisitions in 2024 expanded Asker’s presence to 17 countries and added 1,200 employees, strengthening positions in key markets and product segments.

• Sustainability remains central, with Asker awarded a Platinum EcoVadis rating and early adoption of CSRD/ESRS standards.

• The Board proposes no dividend for 2024, retaining earnings to support future growth.

Financial highlights

• Net sales: SEK 15,025m (up 12% year-over-year; 17% on comparable basis).

• Adjusted EBITA: SEK 1,362m (up 25% year-over-year); margin 9.1%.

• EBITA: SEK 1,207m; EBIT: SEK 966m; Net profit: SEK 376m (up from SEK 205m).

• Net debt: SEK 3,091m; Net debt/EBITDA (adj.): 2.1x.

• Cash flow from operations: SEK 1,227m.

• Investments: SEK 158m in tangible assets, SEK 191m in intangibles.

Outlook and guidance

• Continued focus on organic growth and acquisitions, with further expansion planned in Europe.

• Ongoing investments in sustainability, digitalization, and operational efficiency.

• No dividend proposed for 2024; all earnings to be retained for growth.

• Market expected to remain stable with long-term growth drivers such as aging population and chronic disease prevalence.